Articles from Nia Therapeutics

Nia Therapeutics announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its Smart Neurostimulation System (SNS) for the treatment of episodic memory loss in adult patients with prior moderate-to-severe traumatic brain injury (TBI) and persistent memory deficits. The SNS is the first device to receive Breakthrough designation for TBI-related memory loss. There is significant unmet need in this indication, with no FDA-cleared or approved therapies to treat memory loss and more than 4.3 million Americans living with TBI-related disability.1

Nia Therapeutics announced publication in Brain Stimulation of the first in vivo validation of its Smart Neurostimulation System (SNS), a wireless, implantable brain-computer interface designed for closed-loop treatment of memory disorders.